Retreatment of Multiple Myeloma with Previously Refractory Drugs.

Autor:	Goel U; Mayo Clinic, United States., Charalampous C; Mayo Clinic, Rochester, Minnesota, United States., Kapoor P; Mayo Clinic, Rochester, MN, Rochester, Minnesota, United States., Binder M; Mayo Clinic, Rochester, Minnesota, United States., Buadi FK; Mayo clinic, Rochester, Minnesota, United States., Dingli D; Mayo Clinic, Rochester, Minnesota, United States., Dispenzieri A; Mayo Clinic, Rochester, Minnesota, United States., Fonder AL; Mayo Clinic, Rochester, Minnesota, United States., Gertz MA; Mayo Clinic, Rochester, Minnesota, United States., Gonsalves WI; Mayo Clinic, Rochester, Minnesota, United States., Hayman SR; Mayo Clinic, Rochester, Minnesota, United States., Hobbs MA; Mayo Clinic, Rochester, Minnesota, United States., Hwa YL; Mayo Clinic, Rochester, Minnesota, United States., Kourelis TV; Mayo Clinic, Rochester, Minnesota, United States., Lacy MQ; Mayo Clinic, Rochester, Minnesota, United States., Leung N; Mayo Clinic, Rochester, Minnesota, United States., Lin Y; Mayo Clinic, Rochester, Minnesota, United States., Warsame R; Mayo Clinic, Rochester, Minnesota, United States., Kyle RA; Mayo Clinic, Rochester, Minnesota, United States., Rajkumar SV; Mayo Clinic, Rochester, Minnesota, United States., Kumar SK; Mayo Clinic, Rochester, Minnesota, United States.
Jazyk:	angličtina
Zdroj:	Blood advances [Blood Adv] 2024 Nov 13. Date of Electronic Publication: 2024 Nov 13.
DOI:	10.1182/bloodadvances.2024014723
Abstrakt:	As patients with relapsed/refractory multiple myeloma (RRMM) continue to live longer, they might get exposed to most available drugs and drug classes during the disease course. For such late line RRMM or among patients without access to novel therapies, retreatment with a drug that the disease had previously been refractory to might be one option. In this retrospective study, we describe 315 patients with RRMM at our institution that were retreated with a drug that the disease had been previously refractory to. We found an overall response rate of 56.2%, and a median progression free survival (PFS) of 11 months with retreatment. Patients with a longer time on initial therapy with the index drug (>28.4 months) had a superior PFS with retreatment (median PFS 16.9 months vs 8.1 months, p<0.001). Similarly, patients with a longer time gap between the initial line of therapy with index drug and retreatment with index drug (>46.1 months) had a better PFS with retreatment (28.2 vs 8.9 months, p=0.016). In conclusion, retreatment with a previously refractory drug is a viable therapeutic option for RRMM, with the most significant benefit derived in disease demonstrating sensitivity to initial drug exposure, and among those with a longer gap between initial drug exposure and retreatment. (Copyright © 2024 American Society of Hematology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu